Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SA1211
- Development stage
- Phase 1
- Lead developer
- Suzhou Siran Biotech
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
- Administration
- Subcutaneous
01
Overview
SA1211 is a first-in-class, dual-targeting small interfering RNA (siRNA) dimer, conjugated with N-acetylgalactosamine (GalNAc), being developed for the potential functional cure of chronic hepatitis B. SA1211 directly silences hepatitis B virus (HBV) gene expression and potently suppresses viral replication via inhibition of HBX (hepatitis B virus X protein) and, additionally, inhibits programmed death-ligand 1 (PDL1). This simultaneous action both eradicates the virus and activates the acquired immune response, which may prevent viral rebound following treatment discontinuation. Developed by Suzhou Siran Biotechnology, SA1211 is currently in late preclinical development.
- Other names
- SA-1211SA1211SA 1211
02
Targets
HBV X RNA (Hepatitis B virus X region RNA transcript)HBx (Hepatitis B virus X protein)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on SA1211.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SA1211.